Changes

{{#seo:

{{#seo:

|title=Amavata  

|title=Amavata  

|type=article

|type=article

}}

}}

<div style='text-align:justify;'>

<p style='text-align:justify;'>The clinical condition in which aggravated [[vata]] is associated with metabolic toxins (ama) and mainly affects joints is termed as ‘amavata’. This condition closely resembles with rheumatoid arthritis. The main culprit behind this disease is the deranged digestion and metabolism (agni). Arthralgia, stiffness and swellings of joint are main clinical features. The treatment is focused to improve digestion and metabolism and maintain equilibrium of [[vata dosha]]. Detail description of amavata as a separate disease entity is observed in the text of Madhava Nidana.

The clinical condition in which aggravated [[vata]] is associated with metabolic toxins (ama) and mainly affects joints is termed as ‘amavata’. This condition closely resembles with rheumatoid arthritis. The main culprit behind this disease is the deranged digestion and metabolism (agni). Arthralgia, stiffness and swellings of joint are main clinical features. The treatment is focused to improve digestion and metabolism and maintain equilibrium of [[vata dosha]]. Detail description of amavata as a separate disease entity is observed in the text of Madhava Nidana.

<br/>A comparative study of the pathophysiology of this disease by [[Ayurveda]] and allopathic system reveals that modern medicine emphasizes on control of  inflammation with use of NSAIDS, immunosuppressants and TNF blockers. This is an “offence strategy” which has rapid response but needs to be continued indefinitely and has high incidence of toxicity. On the other hand [[Ayurveda]] follows primarily a “defense strategy” which takes longer time to control inflammation and the symptoms but incidence of toxicity is very little, if at all. In patients with acute inflammation and severe discomfort, initial treatment should be with immunosuppressants and TNF blockers. On control of acute symptoms ayurvedic treatment should be continued. This combined ([[Symbiohealth]]) approach in the management of disease can give insight into the genetic and epigenetic phenomenon and opens the doors for groundbreaking research.<ref>Basisht GK, Singh RH, Chandola H. Management of rheumatoid arthritis (Aamavata) using symbiohealth healthcare system. AYU [serial online] 2012 [cited 2021 Jul 24];33:466-74. Available from: https://www.ayujournal.org/text.asp?2012/33/4/466/110513</ref> This article describes the etiopathogenesis and management of amavata. </p>

A comparative study of the pathophysiology of this disease by [[Ayurveda]] and allopathic system reveals that modern medicine emphasizes on control of  inflammation with use of NSAIDS, immunosuppressants and TNF blockers. This is an “offence strategy” which has rapid response but needs to be continued indefinitely and has high incidence of toxicity. On the other hand [[Ayurveda]] follows primarily a “defense strategy” which takes longer time to control inflammation and the symptoms but incidence of toxicity is very little, if at all. In patients with acute inflammation and severe discomfort, initial treatment should be with immunosuppressants and TNF blockers. On control of acute symptoms ayurvedic treatment should be continued. This combined ([[Symbiohealth]]) approach in the management of disease can give insight into the genetic and epigenetic phenomenon and opens the doors for groundbreaking research.<ref>Basisht GK, Singh RH, Chandola H. Management of rheumatoid arthritis (Aamavata) using symbiohealth healthcare system. AYU [serial online] 2012 [cited 2021 Jul 24];33:466-74. Available from: https://www.ayujournal.org/text.asp?2012/33/4/466/110513</ref> This article describes the etiopathogenesis and management of amavata.  

'''National Ayurveda Morbidity Code''': EC-6

'''National Ayurveda Morbidity Code''': EC-6

|label2 = Authors

|label2 = Authors

|data2 = Aneesh E.G., Deole Y.S.

|data2 = Aneesh E.G., [[Yogesh Deole|Deole Y.S.]]

|label3 = Reviewed by  

|label3 = Reviewed by  

|data3 = Basisht G.

|data3 = [[Gopal Basisht|Basisht G.]]

|label4 = Affiliations

|label4 = Affiliations

|data5 = carakasamhita@gmail.com

|data5 = carakasamhita@gmail.com

|label6 = Date of first publication:

|label6 = Publisher

|data6 = August 18, 2021

|data6 = [[Charak Samhita Research, Training and Development Centre]], I.T.R.A., Jamnagar, India

|label7 = DOI

|label7 = Date of first publication:

|data7 = In process

 

|label8 = DOI

|data8 = 10.47468/CSNE.2021.e01.s09.072

}}

}}